Neogenomics (NEO) Total Non-Current Liabilities (2012 - 2026)

Neogenomics has reported Total Non-Current Liabilities for 15 years, with the latest figure at $433.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities changed 0.07% year-over-year to $433.2 million; the trailing twelve-month figure through Mar 2026 stood at $433.2 million (changed 0.07% YoY), and the FY2025 full-year result was $435.0 million, changed 0.12% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $433.2 million, roughly flat from $435.0 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $672.5 million in Q1 2022, with the low at $433.2 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $550.0 million across 5 years, with a median of $637.9 million in 2023.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities rose 15.36% — and 2024, when it plunged 32.47%.
• Neogenomics' Total Non-Current Liabilities stood at $652.1 million in 2022, then decreased by 1.33% to $643.4 million in 2023, then sank by 32.47% to $434.5 million in 2024, then advanced by 0.12% to $435.0 million in 2025, then retreated by 0.41% to $433.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $433.2 million (Q1 2026), $435.0 million (Q4 2025), and $438.6 million (Q3 2025), per Business Quant data.